LCM
REGN icon

Levitt Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Levitt Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-50
Closed -$14K – 63
2013
Q4 		$14K Hold
50
– – 0.02% 51
2013
Q3 		$16K Buy
+50
New +$13.2K 0.02% 45

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Levitt Capital Management's REGN Position: Q1 2014 in Review

Levitt Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2014, closing a stake of 50 shares — an estimated $14K sold.

Levitt Capital Management first reported a position in REGN in Q3 2013 and held it in 2 quarters. The position peaked at $16K in Q3 2013. 453 funds tracked by Wall St. Rank hold REGN as of Q1 2014.

  • Levitt Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Levitt Capital Management sold 50 Regeneron Pharmaceuticals shares in Q1 2014, an estimated $14K.
  • Levitt Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Levitt Capital Management's Regeneron Pharmaceuticals position peaked at $16K in Q3 2013.
  • 453 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2014.

Based on Levitt Capital Management's 13F filing for Q1 2014, filed 24 Apr 2014.